A Multicenter, dOuble-blind, ranDomized, Placebo-controlled, Parallel-group Study to Determine the effIcacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With FabrY Disease
Phase of Trial: Phase III
Latest Information Update: 18 Feb 2019
At a glance
- Drugs Lucerastat (Primary)
- Indications Fabry's disease
- Focus Registrational; Therapeutic Use
- Acronyms MODIFY
- Sponsors Idorsia Pharmaceuticals
- 07 Feb 2019 According to the Idorsia Pharmaceuticals media release, data from this trial is expected in the first half of 2020.
- 18 Dec 2018 Planned End Date changed from 15 Nov 2019 to 7 Jan 2020.
- 18 Dec 2018 Planned primary completion date changed from 8 Nov 2019 to 7 Dec 2019.